全球基因组编辑市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势和预测

全球基因组编辑市场需求预计将从 2023 年的 83.6 亿美元达到近 354.9 亿美元的市场规模，2024-2032 年研究期间复合年增长率为 17.42%。

基因组编辑是指一套先进的生物技术，可以精确修改生物体的遗传物质。透过利用 CRISPR-Cas9 等方法，研究人员可以瞄准并改变特定的 DNA 序列，促进基因突变的纠正、所需性状的增强或基因功能的研究。这项技术在医学、农业和研究等各个领域具有变革潜力，可以进行量身定制的基因干预措施，以改善健康状况、提高作物产量并增进科学认识。

市场动态

CRISPR 和其他编辑技术的进步为基因操作提供了更精确和更容易的方法，促进了市场扩张。基因组编辑在生物医学研究中发挥关键作用，有助于了解疾病机制、药物发现和潜在疗法，并推动其在生物製药领域的需求。遗传性疾病的盛行率日益增加，推动了针对基因突变的疗法的开发，进一步推动了市场的发展。在农业和畜牧业中，这种编辑用于增强性状、提高产量和开发抗病品种，从而促进农业生物技术的发展。支持性的监管框架、增加的研发投资以及基因组编辑在治疗各种疾病方面的治疗潜力推动了市场的扩张。机构和产业参与者之间的合作推动创新，带来新颖的应用和疗法。儘管面临脱靶效应和伦理问题等挑战，但在技术进步及其彻底改变不同领域的生物医学研究、农业和治疗干预的潜力的推动下，基因组编辑市场仍在不断扩大。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球基因组编辑市场的各个细分市场进行了包容性评估。基因组编辑产业的成长和趋势为这项研究提供了整体方法。

市场区隔

基因组编辑市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略家确定相应产品或服务的目标人口统计数据以及即将到来的机会。

依技术

• CRISPR-Cas9
• TALEN/MegaTAL
• ZFN
• 大范围核酸酶
• 其他的

按交货方式

• 离体
• 体内

按申请

• 基因工程（细胞株工程、动物基因工程、植物基因工程等）
• 临床应用（诊断、治疗发展）

按模式

• 合约
• 内部

按最终用途

• 生物技术和製药公司
• 学术和政府研究机构
• 合约研究组织

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲基因组编辑市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。基因组编辑市场的主要参与者包括Merck KGaA、Cibus Inc.、Recombinetics、Sangamo Therapeutics、Editas Medicine、Precision BioSciences、Crispr Therapeutics、Intellia Therapeutics Inc.、Cari Biosciences Inc.、Cellectis SA、Aetley、Takara Inc. 、Horizo​​​​n Discovery Ltd. (Revvity Inc.)、丹纳赫公司、Transposagen Biopharmaceuticals Inc.、Genscript Biotech Corp.、New England Biolabs。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

• 报告说明
  • 客观的
  • 目标受众
  • 独特的销售主张 (USP) 和产品
• 研究范围
• 研究方法
  • 市场研究过程
  • 市场研究方法论

第 2 章：执行摘要

• 市集亮点
• 全球市场概况

第 3 章：基因组编辑 - 产业分析

• 简介 - 市场动态
• 市场驱动因素
• 市场限制
• 机会
• 产业动态
• 波特五力分析
• 市场吸引力分析
  • 按技术分類的市场吸引力分析
  • 以交付方式分析市场吸引力
  • 市场吸引力分析：依应用分类
  • 按模式分類的市场吸引力分析
  • 按最终用途分類的市场吸引力分析
  • 市场吸引力分析：按地区

第 4 章：价值链分析

• 价值链分析
• 原料分析
  • 原料清单
  • 原料厂商清单
  • 主要原物料价格走势
• 潜在买家名单
• 行销管道
  • 直效行销
  • 间接行销
  • 行销通路发展趋势

第 5 章：全球基因组编辑市场分析：依技术分类

• 依技术概述
• 按技术进行历史和预测数据分析
• CRISPR-Cas9
• TALEN/MegaTAL
• ZFN
• 大范围核酸酶
• 其他的

第 6 章：全球基因组编辑市场分析：以交付方式

• 按交付方式概述
• 按交付方式进行历史和预测资料分析
• 离体
• 体内

第 7 章：全球基因组编辑市场分析：依应用分类

• 概述：按应用
• 历史与预测资料分析：按应用分类
• 基因工程（细胞株工程、动物基因工程、植物基因工程等）
• 临床应用（诊断、治疗发展）

第 8 章：全球基因组编辑市场分析：按模式

• 按模式概述
• 按模式进行历史和预测资料分析
• 合约
• 内部

第 9 章：全球基因组编辑市场分析：依最终用途分类

• 按最终用途分类的概述
• 按最终用途分类的历史和预测资料分析
• 生物技术和製药公司
• 学术和政府研究机构
• 合约研究组织

第 10 章：全球基因组编辑市场分析：依地理位置

• 区域展望
• 介绍
• 北美销售分析
  • 概览、历史与预测资料销售分析
  • 北美按细分市场销售分析
  • 北美按国家销售分析
  • 美国销售分析
  • 加拿大销售分析
  • 墨西哥销售分析
• 欧洲销售分析
  • 概览、历史与预测资料销售分析
  • 欧洲按细分市场销售分析
  • 欧洲按国家销售分析
  • 英国销售分析
  • 法国销售分析
  • 德国销售分析
  • 义大利销售分析
  • 俄罗斯销售分析
  • 欧洲其他地区销售分析
• 亚太地区销售分析
  • 概览、历史与预测资料销售分析
  • 亚太地区按细分市场销售分析
  • 亚太地区按国家销售分析
  • 中国销售分析
  • 印度销售分析
  • 日本销售分析
  • 韩国销售分析
  • 澳洲销售分析
  • 东南亚销售分析
  • 亚太地区其他地区销售分析
• 拉丁美洲销售分析
  • 概览、历史与预测资料销售分析
  • 拉丁美洲按细分市场销售分析
  • 拉丁美洲按国家销售分析
  • 巴西销售分析
  • 阿根廷销售分析
  • 秘鲁销售分析
  • 智利销售分析
  • 拉丁美洲其他地区销售分析
• 中东和非洲销售分析
  • 概览、历史与预测资料销售分析
  • 中东和非洲按细分市场销售分析
  • 中东和非洲按国家销售分析
  • 沙乌地阿拉伯销售分析
  • 阿联酋销售分析
  • 以色列销售分析
  • 南非销售分析
  • 中东其他地区和非洲销售分析

第 11 章：基因组编辑公司的竞争格局

• 基因组编辑市场竞争
• 伙伴关係/协作/协议
• 併购
• 新产品发布
• 其他发展

第 12 章：公司简介

• 顶级公司市占率分析
• 市场集中度
• Merck KGaA
• 公司概况
• 公司收入
• 产品
• 最新动态
• Cibus Inc.
• 公司概况
• 公司收入
• 产品
• 最新动态
• Recombinetics
• 公司概况
• 公司收入
• 产品
• 最新动态
• Sangamo Therapeutics
• 公司概况
• 公司收入
• 产品
• 最新动态
• Editas Medicine
• 公司概况
• 公司收入
• 产品
• 最新动态
• Precision BioSciences
• 公司概况
• 公司收入
• 产品
• 最新动态
• Crispr Therapeutics
• 公司概况
• 公司收入
• 产品
• 最新动态
• Intellia Therapeutics Inc.
• 公司概况
• 公司收入
• 产品
• 最新动态
• Caribou Biosciences Inc
• 公司概况
• 公司收入
• 产品
• 最新动态
• Cellectis SA
• 公司概况
• 公司收入
• 产品
• 最新动态
• AstraZeneca
• 公司概况
• 公司收入
• 产品
• 最新动态
• Takara Bio Inc.
• 公司概况
• 公司收入
• 产品
• 最新动态
• Horizon Discovery Ltd. (Revvity Inc.)
• 公司概况
• 公司收入
• 产品
• 最新动态
• Danaher Corporation
• 公司概况
• 公司收入
• 产品
• 最新动态
• Transposagen Biopharmaceuticals Inc.
• 公司概况
• 公司收入
• 产品
• 最新动态
• Genscript Biotech Corp
• 公司概况
• 公司收入
• 产品
• 最新动态
• New England Biolabs
• 公司概况
• 公司收入
• 产品
• 最新动态

註 - 在公司概况中，财务详细资讯和最新发展视情况而定，或对私人公司而言可能不包括在内

The global demand for Genome Editing Market is presumed to reach the market size of nearly USD 35.49 Billion by 2032 from USD 8.36 Billion in 2023 with a CAGR of 17.42% under the study period 2024-2032.

Genome editing refers to a suite of advanced biotechnological techniques that enable precise modification of an organism's genetic material. By utilizing methods such as CRISPR-Cas9, researchers can target and alter specific DNA sequences, facilitating the correction of genetic mutations, enhancement of desirable traits, or investigation of gene function. This technology holds transformative potential across various fields, including medicine, agriculture, and research, allowing for tailored genetic interventions to improve health outcomes, increase crop yields, and advance scientific understanding.

MARKET DYNAMICS

Advancements in CRISPR and other editing technologies offer more precise and accessible methods for genetic manipulation, fostering market expansion. Genome editing plays a pivotal role in biomedical research, aiding in understanding disease mechanisms, drug discovery, and potential therapies, driving its demand in the biopharmaceutical sector. The increasing prevalence of genetic disorders fuels the development of therapies targeting genetic mutations, further propelling the market. In agriculture and livestock, this editing is used to enhance traits, improve yields, and develop disease-resistant varieties, contributing to its growth in agricultural biotechnology. Supportive regulatory frameworks, increased R&D investments, and the therapeutic potential of genome editing in treating various conditions fuel market expansion. Collaborations among institutions and industry players drive innovation, leading to novel applications and therapies. Despite challenges like off-target effects and ethical concerns, the genome editing market continues to expand, driven by technological advancements and its potential to revolutionize biomedical research, agriculture, and therapeutic interventions across diverse sectors.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Genome Editing. The growth and trends of Genome Editing industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Genome Editing market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Technology

• CRISPR-Cas9
• TALENs/MegaTALs
• ZFN
• Meganuclease
• Others

By Delivery Method

• Ex-vivo
• In-vivo

By Application

• Genetic Engineering (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Others)
• Clinical Applications (Diagnostics, Therapy Development)

By Mode

• Contract
• In-House

By End-use

• Biotechnology and Pharmaceutical Companies
• Academic and Government Research Institutes
• Contract Research Organizations

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Genome Editing market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Genome Editing market include Merck KGaA, Cibus Inc., Recombinetics, Sangamo Therapeutics, Editas Medicine, Precision BioSciences, Crispr Therapeutics, Intellia Therapeutics Inc., Caribou Biosciences Inc, Cellectis S.A., AstraZeneca, Takara Bio Inc., Horizon Discovery Ltd. (Revvity Inc.), Danaher Corporation, Transposagen Biopharmaceuticals Inc., Genscript Biotech Corp, New England Biolabs. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. GENOME EDITING - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Technology
  • 3.7.2 Market Attractiveness Analysis By Delivery Method
  • 3.7.3 Market Attractiveness Analysis By Application
  • 3.7.4 Market Attractiveness Analysis By Mode
  • 3.7.5 Market Attractiveness Analysis By End-use
  • 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL GENOME EDITING MARKET ANALYSIS BY TECHNOLOGY

• 5.1. Overview By Technology
• 5.2. Historical and Forecast Data Analysis By Technology
• 5.3. CRISPR-Cas9 Historic and Forecast Sales By Regions
• 5.4. TALENs/MegaTALs Historic and Forecast Sales By Regions
• 5.5. ZFN Historic and Forecast Sales By Regions
• 5.6. Meganuclease Historic and Forecast Sales By Regions
• 5.7. Others Historic and Forecast Sales By Regions

6. GLOBAL GENOME EDITING MARKET ANALYSIS BY DELIVERY METHOD

• 6.1. Overview By Delivery Method
• 6.2. Historical and Forecast Data Analysis By Delivery Method
• 6.3. Ex-vivo Historic and Forecast Sales By Regions
• 6.4. In-vivo Historic and Forecast Sales By Regions

7. GLOBAL GENOME EDITING MARKET ANALYSIS BY APPLICATION

• 7.1. Overview By Application
• 7.2. Historical and Forecast Data Analysis By Application
• 7.3. Genetic Engineering (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Others) Historic and Forecast Sales By Regions
• 7.4. Clinical Applications (Diagnostics, Therapy Development) Historic and Forecast Sales By Regions

8. GLOBAL GENOME EDITING MARKET ANALYSIS BY MODE

• 8.1. Overview By Mode
• 8.2. Historical and Forecast Data Analysis By Mode
• 8.3. Contract Historic and Forecast Sales By Regions
• 8.4. In-House Historic and Forecast Sales By Regions

9. GLOBAL GENOME EDITING MARKET ANALYSIS BY END-USE

• 9.1. Overview By End-use
• 9.2. Historical and Forecast Data Analysis By End-use
• 9.3. Biotechnology and Pharmaceutical Companies Historic and Forecast Sales By Regions
• 9.4. Academic and Government Research Institutes Historic and Forecast Sales By Regions
• 9.5. Contract Research Organizations Historic and Forecast Sales By Regions

10. GLOBAL GENOME EDITING MARKET ANALYSIS BY GEOGRAPHY

• 10.1. Regional Outlook
• 10.2. Introduction
• 10.3. North America Sales Analysis
  • 10.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.3.2 North America By Segment Sales Analysis
  • 10.3.3 North America By Country Sales Analysis
  • 10.3.4 United States Sales Analysis
  • 10.3.5 Canada Sales Analysis
  • 10.3.6 Mexico Sales Analysis
• 10.4. Europe Sales Analysis
  • 10.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.4.2 Europe By Segment Sales Analysis
  • 10.4.3 Europe By Country Sales Analysis
  • 10.4.4 United Kingdom Sales Analysis
  • 10.4.5 France Sales Analysis
  • 10.4.6 Germany Sales Analysis
  • 10.4.7 Italy Sales Analysis
  • 10.4.8 Russia Sales Analysis
  • 10.4.9 Rest Of Europe Sales Analysis
• 10.5. Asia Pacific Sales Analysis
  • 10.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.5.2 Asia Pacific By Segment Sales Analysis
  • 10.5.3 Asia Pacific By Country Sales Analysis
  • 10.5.4 China Sales Analysis
  • 10.5.5 India Sales Analysis
  • 10.5.6 Japan Sales Analysis
  • 10.5.7 South Korea Sales Analysis
  • 10.5.8 Australia Sales Analysis
  • 10.5.9 South East Asia Sales Analysis
  • 10.5.10 Rest Of Asia Pacific Sales Analysis
• 10.6. Latin America Sales Analysis
  • 10.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.6.2 Latin America By Segment Sales Analysis
  • 10.6.3 Latin America By Country Sales Analysis
  • 10.6.4 Brazil Sales Analysis
  • 10.6.5 Argentina Sales Analysis
  • 10.6.6 Peru Sales Analysis
  • 10.6.7 Chile Sales Analysis
  • 10.6.8 Rest of Latin America Sales Analysis
• 10.7. Middle East & Africa Sales Analysis
  • 10.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.7.2 Middle East & Africa By Segment Sales Analysis
  • 10.7.3 Middle East & Africa By Country Sales Analysis
  • 10.7.4 Saudi Arabia Sales Analysis
  • 10.7.5 UAE Sales Analysis
  • 10.7.6 Israel Sales Analysis
  • 10.7.7 South Africa Sales Analysis
  • 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE GENOME EDITING COMPANIES

• 11.1. Genome Editing Market Competition
• 11.2. Partnership/Collaboration/Agreement
• 11.3. Merger And Acquisitions
• 11.4. New Product Launch
• 11.5. Other Developments

12. COMPANY PROFILES OF GENOME EDITING INDUSTRY

• 12.1. Top Companies Market Share Analysis
• 12.2. Market Concentration Rate
• 12.3. Merck KGaA
  • 12.3.1 Company Overview
  • 12.3.2 Company Revenue
  • 12.3.3 Products
  • 12.3.4 Recent Developments
• 12.4. Cibus Inc.
  • 12.4.1 Company Overview
  • 12.4.2 Company Revenue
  • 12.4.3 Products
  • 12.4.4 Recent Developments
• 12.5. Recombinetics
  • 12.5.1 Company Overview
  • 12.5.2 Company Revenue
  • 12.5.3 Products
  • 12.5.4 Recent Developments
• 12.6. Sangamo Therapeutics
  • 12.6.1 Company Overview
  • 12.6.2 Company Revenue
  • 12.6.3 Products
  • 12.6.4 Recent Developments
• 12.7. Editas Medicine
  • 12.7.1 Company Overview
  • 12.7.2 Company Revenue
  • 12.7.3 Products
  • 12.7.4 Recent Developments
• 12.8. Precision BioSciences
  • 12.8.1 Company Overview
  • 12.8.2 Company Revenue
  • 12.8.3 Products
  • 12.8.4 Recent Developments
• 12.9. Crispr Therapeutics
  • 12.9.1 Company Overview
  • 12.9.2 Company Revenue
  • 12.9.3 Products
  • 12.9.4 Recent Developments
• 12.10. Intellia Therapeutics Inc.
  • 12.10.1 Company Overview
  • 12.10.2 Company Revenue
  • 12.10.3 Products
  • 12.10.4 Recent Developments
• 12.11. Caribou Biosciences Inc
  • 12.11.1 Company Overview
  • 12.11.2 Company Revenue
  • 12.11.3 Products
  • 12.11.4 Recent Developments
• 12.12. Cellectis S.A.
  • 12.12.1 Company Overview
  • 12.12.2 Company Revenue
  • 12.12.3 Products
  • 12.12.4 Recent Developments
• 12.13. AstraZeneca
  • 12.13.1 Company Overview
  • 12.13.2 Company Revenue
  • 12.13.3 Products
  • 12.13.4 Recent Developments
• 12.14. Takara Bio Inc.
  • 12.14.1 Company Overview
  • 12.14.2 Company Revenue
  • 12.14.3 Products
  • 12.14.4 Recent Developments
• 12.15. Horizon Discovery Ltd. (Revvity Inc.)
  • 12.15.1 Company Overview
  • 12.15.2 Company Revenue
  • 12.15.3 Products
  • 12.15.4 Recent Developments
• 12.16. Danaher Corporation
  • 12.16.1 Company Overview
  • 12.16.2 Company Revenue
  • 12.16.3 Products
  • 12.16.4 Recent Developments
• 12.17. Transposagen Biopharmaceuticals Inc.
  • 12.17.1 Company Overview
  • 12.17.2 Company Revenue
  • 12.17.3 Products
  • 12.17.4 Recent Developments
• 12.18. Genscript Biotech Corp
  • 12.18.1 Company Overview
  • 12.18.2 Company Revenue
  • 12.18.3 Products
  • 12.18.4 Recent Developments
• 12.19. New England Biolabs
  • 12.19.1 Company Overview
  • 12.19.2 Company Revenue
  • 12.19.3 Products
  • 12.19.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers: Impact Analysis
• Restraints: Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• Analysis By Technology (USD MN)
• CRISPR-Cas9 Market Sales By Geography (USD MN)
• TALENs/MegaTALs Market Sales By Geography (USD MN)
• ZFN Market Sales By Geography (USD MN)
• Meganuclease Market Sales By Geography (USD MN)
• Others Market Sales By Geography (USD MN)
• Analysis By Delivery Method (USD MN)
• Ex-vivo Market Sales By Geography (USD MN)
• In-vivo Market Sales By Geography (USD MN)
• Analysis By Application (USD MN)
• Genetic Engineering (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Others) Market Sales By Geography (USD MN)
• Clinical Applications (Diagnostics, Therapy Development) Market Sales By Geography (USD MN)
• Analysis By Mode (USD MN)
• Contract Market Sales By Geography (USD MN)
• In-House Market Sales By Geography (USD MN)
• Analysis By End-use (USD MN)
• Biotechnology and Pharmaceutical Companies Market Sales By Geography (USD MN)
• Academic and Government Research Institutes Market Sales By Geography (USD MN)
• Contract Research Organizations Market Sales By Geography (USD MN)
• Global Genome Editing Market Sales By Geography (USD MN)
• North America Market Analysis (USD MN)
• United States Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate By Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Genome Editing Report
• Market Research Process
• Market Research Methodology
• Global Genome Editing Market Size, By Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis By Technology
• Market Attractiveness Analysis By Delivery Method
• Market Attractiveness Analysis By Application
• Market Attractiveness Analysis By Mode
• Market Attractiveness Analysis By End-use
• Market Attractiveness Analysis By Region
• Value Chain Analysis
• Global Market Analysis By Technology (USD MN)
• CRISPR-Cas9 Market Sales By Geography (USD MN)
• TALENs/MegaTALs Market Sales By Geography (USD MN)
• ZFN Market Sales By Geography (USD MN)
• Meganuclease Market Sales By Geography (USD MN)
• Others Market Sales By Geography (USD MN)
• Global Market Analysis By Delivery Method (USD MN)
• Ex-vivo Market Sales By Geography (USD MN)
• In-vivo Market Sales By Geography (USD MN)
• Global Market Analysis By Application (USD MN)
• Genetic Engineering (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Others) Market Sales By Geography (USD MN)
• Clinical Applications (Diagnostics, Therapy Development) Market Sales By Geography (USD MN)
• Global Market Analysis By Mode (USD MN)
• Contract Market Sales By Geography (USD MN)
• In-House Market Sales By Geography (USD MN)
• Global Market Analysis By End-use (USD MN)
• Biotechnology and Pharmaceutical Companies Market Sales By Geography (USD MN)
• Academic and Government Research Institutes Market Sales By Geography (USD MN)
• Contract Research Organizations Market Sales By Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.